Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

join our enewsletter | translate

IPF Research

See below for the latest in research news related to Idiopathic Pulmonary Fibrosis (IPF). This is where the PFF will share relevant news articles, press releases, and study results in the field of IPF.

First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis
- by Kelsey Overberg
- Jan 11, 2021
Full story: First Patient Enrolls In PRECISIONS Study For Treatment Of Idiopathic Pulmonary Fibrosis
Phase 3 trial of Novavax investigational COVID-19 vaccine opens
- by Kelsey Overberg
- Dec 29, 2020
Full story: Phase 3 trial of Novavax investigational COVID-19 vaccine opens
FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
- by Kelsey Overberg
- Dec 21, 2020
Full story: FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
- by Kelsey Overberg
- Dec 18, 2020
Full story: Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
- by Kelsey Overberg
- Dec 18, 2020
Full story: Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
- by Kelsey Overberg
- Dec 18, 2020
Full story: Pfizer and BioNTech Conclude Phase 3 Study of COVID-19 Vaccine Candidate, Meeting All Primary Efficacy Endpoints
AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
- by Kelsey Overberg
- Dec 18, 2020
Full story: AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19
- by Kelsey Overberg
- Dec 16, 2020
Full story: OncoImmune’s SACCOVID™ (CD24Fc) Exhibits Superb Therapeutic Efficacy—A Potential Breakthrough in Treating Severe and Critical COVID-19
Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
- by Kelsey Overberg
- Dec 15, 2020
Full story: Bellerophon Therapeutics Announces Results of Interim Analysis of Phase 3 COViNOX Study of INOpulse® for the Treatment of COVID-19
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
- by Kelsey Overberg
- Dec 15, 2020
Full story: Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine
- by Kelsey Overberg
- Dec 15, 2020
Full story: FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine
United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
- by Kelsey Overberg
- Dec 11, 2020
Full story: United Therapeutics Highlights Poster Presentations from the Recent CHEST 2020 Meeting
United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
- by Kelsey Overberg
- Dec 11, 2020
Full story: United Therapeutics Receives FDA Orphan Drug Designation For Treprostinil For The Treatment Of Idiopathic Pulmonary Fibrosis
Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
- by Kelsey Overberg
- Dec 8, 2020
Full story: Galecto Publishes GB0139 Phase 2a Idiopathic Pulmonary Fibrosis (IPF) Results in European Respiratory Journal, Showing Marked Impact on Several IPF Biomarkers
Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
- by Kelsey Overberg
- Dec 4, 2020
Full story: Bellerophon Therapeutics Announces First Patient Enrolled in Phase 3 REBUILD Study Evaluating INOpulse® for the Treatment of Fibrotic Interstitial Lung Disease
Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
- by Kelsey Overberg
- Sep 23, 2020
Full story: Bellerophon Therapeutics Announces Publication of Cohort 1 of iNO-PF Phase 2/3 Study in the CHEST Journal and Participation in Webinar to Discuss Clinical Results
Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
- by Kelsey Overberg
- Sep 16, 2020
Full story: Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients
Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162B2 against COVID-19
- by Kelsey Overberg
- Sep 15, 2020
Full story: Pfizer and BioNTech share positive early data on lead mRNA vaccine candidate BNT162B2 against COVID-19

footer_txt_bbl

Book a PFF Ambassador for your event. Call 844.TalkPFF >

Life with PF

Our Role

Get Involved

Ways to Give

Medical Community

Sponsors and Exhibitors

The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a four-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter

PRIVACY POLICY TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation | 230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741 | f. 866.587.9158 | info@pulmonaryfibrosis.org

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.